数字医学在慢性呼吸系统疾病中实施的常见障碍与促进因素:一项综述的综述。
完整摘要 · 中文译文
背景与研究问题:数字医学在改善呼吸医学诊疗方面具有显著潜力,但其全面应用仍然有限。障碍与促进因素涉及多方利益相关者,且很可能在不同疾病和技术之间具有共性。本研究的研究问题如下:以支气管哮喘、囊性纤维化(CF)、慢性阻塞性肺疾病(COPD)和COVID-19为例,在呼吸系统疾病中实施数字医学的常见障碍、促进因素和可迁移概念是什么? 研究设计与方法:综述的系统综述。检索了三个电子数据库(PubMed、Scopus和Web of Science)以及Cochrane Library,检索时间为2019年9月至2026年5月的综述类出版物。使用AMSTAR-2对纳入的九篇综述进行了评价。对这些综述中引用的原始出版物额外进行了数据提取适用性筛选,最终纳入18篇原始出版物。提取的障碍和促进因素以按疾病和参与者分层的共现网络进行可视化,并映射到两个实施框架(CFIR和Chaudoir等,2013)。 结果:无COVID-19出版物符合纳入标准。哮喘以及部分CF的证据丰富,包含机构层面数据,而COPD证据多样性较低。一项CF项目调查已按照CFIR框架对其数据进行了结构化处理,从而能够独特地完整映射障碍和促进因素。 结论:关于障碍的高质量、框架结构化、网络可视化的证据 数字医学的障碍与促进因素在支气管哮喘中已有研究,在囊性纤维化(CF)中已有部分研究。相比之下,慢性阻塞性肺疾病(COPD)中障碍与促进因素的证据尚不系统。未来研究应依托相关框架,以确保足够的全面性,并促进知识转化为可实施性。 系统综述注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944,PROSPERO,CRD420251070944。
完整摘要 · 英文原文
BACKGROUND AND RESEARCH QUESTION: Digital Medicine offers significant potential for improving care in Respiratory Medicine, yet its full uptake remains limited. Barriers and facilitators involve multiple stakeholders and are likely shared across diseases and technologies. This study had the following research question: What are the common barriers, facilitators, and transferable concepts for implementing Digital Medicine in respiratory diseases, exemplified by bronchial asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and COVID-19? STUDY DESIGN AND METHODS: Systematic review of reviews. Three electronic databases (PubMed, Scopus, and Web of Science), as well as Cochrane Library were searched for review publications from September 2019 through May 2026. Nine included reviews were appraised using AMSTAR-2. Original publications referenced within these reviews were additionally screened for suitability for data extraction, leading to inclusion of 18 original publications. Extracted barriers and facilitators were visualized as disease- and actor-stratified co-occurrence networks and mapped to two implementation frameworks (CFIR and Chaudoir et al. 2013). RESULTS: No COVID-19 publication met inclusion criteria. Asthma and, partially, CF evidence was rich and included institution-level data, while COPD evidence was less diverse. One CF program survey had structured its data according to the CFIR framework, enabling uniquely complete mapping of barriers and facilitators. CONCLUSION: High-quality, framework-structured, network-visualizable evidence on barriers and facilitators to Digital Medicine exists in bronchial asthma and, partially, CF. In contrast, evidence on barriers and facilitators in COPD is not yet systematic. Future studies should be anchored in frameworks for sufficient comprehensiveness and facilitated knowledge translation into implementability. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251070944, PROSPERO, CRD420251070944.